Related Experiment Videos
Antiplatelet and antithrombin therapies in the acute coronary syndromes
J H Alexander1, R A Harrington
1Duke University Medical Center, Durham, NC, USA.
Insights
New antiplatelet drugs show promise for acute coronary syndromes, while new antithrombin agents have mixed results. Further research is ongoing for both treatment types.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Thrombosis in acute coronary syndromes involves platelets and thrombin.
- Current treatments like aspirin and heparin have limitations.
Purpose of the Study:
- To review recent clinical trials of novel antiplatelet and antithrombin agents for acute coronary syndromes.
- To assess the efficacy and safety of these new agents.
Main Methods:
- Review of large clinical trials investigating new antiplatelet drugs (e.g., clopidogrel, glycoprotein IIb/IIIa antagonists).
- Analysis of recent trials involving new antithrombin agents (low-molecular-weight heparins, direct thrombin inhibitors).
Main Results:
- New antiplatelet agents show significant promise in angioplasty and acute coronary syndromes.
- Low-molecular-weight heparins are beneficial for acute coronary syndromes.
- Direct thrombin inhibitors offer modest benefit but carry bleeding risks.
Conclusions:
- Novel antiplatelet therapies represent a promising advancement in managing acute coronary syndromes.
- New antithrombin agents have shown limited success and safety concerns.
- Ongoing trials will further define the role of novel agents in acute coronary syndrome treatment.
Abstract:
The circulating platelet and the soluble coagulation protein thrombin play key roles in the thrombosis responsible for the acute coronary syndromes. The standard antiplatelet and antithrombin agents used today in patients with acute coronary syndromes are aspirin and heparin. Despite our experience with these agents, they both have significant limitations. A number of new antiplatelet drugs, including clopidogrel and the glycoprotein IIb/IIIa antagonists, have been investigated in recent large clinical trials and show significant promise both in patients undergoing angioplasty and those with acute coronary syndromes. The results of recent trials with new antithrombin agents have been less impressive. Low-molecular-weight heparins appear to be beneficial in patients with acute coronary syndromes. Recent trials with direct thrombin inhibitors in patients with acute coronary syndromes have demonstrated modest benefit, but also revealed their narrow therapeutic window and associated risk of bleeding. Further trials with novel antiplatelet and antithrombin agents in patients with acute coronary syndromes are ongoing.